



Carl Bildt, WHO Special Envoy for ACT-A

6 July 2021



RECAP: ACT-A Strategic Review – G20 & G7 statements

The Global Health Summit Rome Declaration "We underline the importance of addressing the ACT-A funding gap, in order to help it fulfil its mandate. We note the intention to conduct a comprehensive strategic review as basis for a possible adaptation and extension of its mandate to the end of 2022"

21 May 2021

The Carbis Bay G7 Summit Communique "We support discussions regarding the extension of the ACT-A mandate into 2022, noting the planned comprehensive review to optimize its effectiveness and accountability."



RECAP: plan for ACT-A Strategic Review

Objectives/dimensions:

- 1. results against the 2 major ACT-A objectives (acceleration & equity)
- 2. impact of ACT-A construct & operating model
- 3. impact of ACT-A financing (inc. pledges, funding rec. & exp).
- 4. impact of broader ecosystem
- 5. recommendations for current ACT-A & potential role beyond Q1 2022

Management arrangements:

- Sponsors: 3 WHO Special Envoys for ACT-A (current & Emeritus)
- Reference group: co-hosts, co-convening agencies, council, industry, CSO & Hub reps
- Implementation: external contractor with no role in ACT-A

Timeline: (i) RFP 2 July (ii) execute contract & initiate in Jul (iii) report in Sept



ACT-A Strategic Review: Updates

- 1. ACT-A Envoys may sponsor
- 2. RFP published 2 July on UN Global Marketplace https://www.ungm.org/Public/Notice/133996
- 3. Council Members to provide input into scope & questions by 30 July (concept note shared on 5 Jul)
- 4. Reference group to be established

For questions please contact: ACTaccelerator@who.int